We evaluated the clinical and immunopathologic features of nonesmall-cell lung cancer with primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors. The rate of smoking was significantly greater in those with primary resistance. The immune microenvironment characterized by low total tumor-infiltrating lymphocytes and negative programmed cell death ligand 1 correlated significantly with primary resistance. Background: Approximately 20% to 30% of nonesmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-activating mutations are not responsive to EGFR tyrosine kinase inhibitors (TKIs). Although primary resistance to EGFR-TKIs has been attributed to various genetic alterations, little is known about the clinical and immunopathologic features of patients with primary resistance. The tumor immune microenvironment, including tumorinfiltrating lymphocytes (TILs) and programmed cell death ligand 1 (PD-L1), has been reported to play an important role in tumor progression in those with NSCLC. However, few studies have directly focused on the relationship between the tumor immune microenvironment and primary resistance to EGFR-TKIs. Materials and Methods: The characteristics of 124 NSCLC patients with EGFR mutations who had received EGFR-TKIs were analyzed. Primary resistance was defined as disease progression within 3 months after EGFR-TKI treatment. Tumor specimens obtained before EGFR-TKI treatment were assessed for the density of TILs expressing CD4 or CD8 and for the expression rate of PD-L1 on tumor cells and tumor-infiltrating immune cells, immunohistochemically. Results: Primary resistance was observed in 13.7% of the patients (17 of 124). A significant difference in smoking history was observed between patients with primary resistance and those with noneprimary resistance. A lower density of total TILs and negative PD-L1 expression on immunohistochemical analysis correlated significantly with primary resistance, in contrast to that with noneprimary resistance. Moreover, the negative PD-L1 expression with low TIL density, indicating immune ignorant phenotype of tumor microenvironment, was observed in those with primary resistance with a significant difference. Conclusion: Smoking and immune ignorance in the tumor microenvironment might result in primary resistance to EGFR-TKIs.
Introduction
Lung cancer is a leading cause of cancer-related death worldwide, 1 and nonesmall-cell lung cancer (NSCLC) accounts for w 80% of all lung cancer cases. 2 Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the mainstay in the treatment of advanced unresectable NSCLC. EGFR-activating mutations are the primary predictive factors of EGFR-TKI therapy outcomes. 3, 4 Among patients with EGFR-activating mutations, w 70% to 80% respond to EGFR-TKIs [5] [6] [7] ; however, acquired drug resistance is frequently observed, leading to disease progression. The mechanisms of acquired resistance have been previously reported. 8 However, w 20% to 30% of patients with EGFR-activating mutations will not be responsive to EGFR-TKIs. 4 Little is known about the clinical and immunopathologic features of patients with primary resistance, although possible mechanisms of primary resistance such as coexisting de novo T790M mutation, 9 v-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog (KRAS ) mutation, 10 mesenchymaleepithelial transition (MET ) amplification, 11 and phosphatase and tensin homolog (PTEN ) loss 12 have been investigated in some preclinical and retrospective studies. Therefore, further studies are required to elucidate the mechanisms of primary resistance.
Previous clinical trials of NSCLC have indicated that high expression of programmed cell death ligand 1 (PD-L1) on tumor cells (TCs) and/or tumor-infiltrating lymphocytes (TILs) was a predictive factor of clinical outcomes for programmed cell death 1 (PD-1)/PD-L1 inhibitor treatment. [13] [14] [15] Previously, we have shown that the number of TILs in B7-H1 (PD-L1)epositive tumor regions is significantly lower than that in B7-H1enegative tumor regions, indicating that B7-H1 expression on TCs might contribute to negative regulation against TILs in NSCLC. 16 Moreover, Akbay et al 17 showed that the activation of EGFR signaling induced the PD-1/PD-L1 pathway, leading to repression of T-cell function, thereby facilitating the escape of TCs from the host immune system. 17 Although the tumor immune microenvironment, including
TILs and PD-L1, has been reported to play an important role in tumor progression in NSCLC, the relationship between the tumor immune microenvironment and primary resistance to EGFR-TKIs is as yet unclear.
In the present study, we evaluated the clinical features of patients with primary resistance to EGFR-TKIs. Furthermore, we assessed the density of TILs and the expression of PD-L1 on TCs and tumor-infiltrating immune cells (ICs) immunohistochemically to analyze the immune microenvironmental features of the primary resistance.
Materials and Methods

Study Patients
The medical ethics committee of the Hokkaido University School of Medicine approved the present study. All the patients provided informed consent. EGFR mutations were identified in tumor tissues using the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method or the Scorpion amplification refractory mutation system method. A total of 124 patients with EGFR mutations who had received EGFR-TKI therapy at the Hokkaido University Hospital, Japan, from January 2004 to January 2015 were screened. The medical records of the patients were reviewed to obtain the clinical and pathologic information. Additional tumor tissue from the same sample previously used for EGFR assessment was available for analysis in all cases. We defined primary resistance as disease progression within 3 months after EGFR-TKI treatment in accordance with a previous report. 18 
Immunohistochemical Staining
Sequential histologic tumor samples, 4 mm thick, were obtained from representative formalin-fixed, paraffin-embedded tumor blocks. The samples were deparaffinized with xylene and rehydrated with graded alcohol. After rinsing with Tris-buffered saline, the samples were processed for antigen retrieval with the Dako EnVision FLEX Target Retrieval Solution (pH 9.0) at 97 C for 20 minutes using the Dako PT Link instrument, according to the manufacturer's instructions. Staining for CD4 and CD8 was performed using an automated staining system (Autostainer Link 48) with antibodies against CD4 (clone 4B12; Ready-to-Use; Dako, Glostrup, Denmark) and CD8 (clone C8/144B; Ready-to-Use; Dako). We used the antiePD-L1 antibody clone SP142 (1:100; Spring Bioscience, Pleasanton, CA) to manually stain for PD-L1. The samples were incubated with SP142 for 30 minutes, and staining was performed using the Dako EnVisio FLEX system. Hematoxylin was used as a counterstain for all samples.
Evaluation of Immunostaining
Because both biopsy samples and surgically resected samples were analyzed in the present study, 2 different algorithms were used to evaluate the density of TILs, according to sample type. For surgically resected samples, we counted TILs expressing CD4 or CD8 in 3 random square areas (1 mm 2 each) in tumor compartments and calculated the average. For biopsy samples, we counted the TILs expressing CD4 or CD8 in all tumor areas on the microscope slide and calculated the density using the entire tumor area. The tumor area was measured using image analysis software (ImageJ). We scored TCs expressing PD-L1 as a percentage of the total TCs and ICs expressing PD-L1 as a percentage of the tumor area, as previously described (TC staining score: TC0, < 1%; TC1, ! 1% to < 5%; TC2, ! 5% to < 50%; TC3, ! 50%; IC staining score: IC0, < 1%; IC1, ! 1% to < 5%; IC2, ! 5% to < 10%; and IC3, ! 10%; Figure 3 ). 14, 19 We stratified PD-L1 staining according to the intensity as follows: score 0, no staining; score 1, weak; score 2, moderate; and score 3, strong staining. We further defined all samples with a score > 1 as positive for PD-L1 expression. Cell counting and scoring were performed by 2 observers, including 1 pathologist (K.C.H), who were unaware of the clinical and pathologic information.
Statistical Analysis
Differences between primary resistance and noneprimary resistance were compared using the Fisher exact test. We used logistic regression models for multivariate analysis. The relationship between TIL density and clinicopathologic variables was analyzed statistically using the Wilcoxon rank sum test. Overall survival (OS) was defined as the time from treatment with EGFR-TKIs to death and was estimated using the Kaplan-Meier method. Differences in survival distributions were evaluated using the log-rank test. Twosided P values < .05 were considered statistically significant. All analyses were performed using the JMP software (JMP Pro, version 12.2.0; SAS Institute Inc, Cary, NC).
Results
Patient Characteristics
The characteristics of the patients at the initiation of EGFR-TKI therapy are summarized in Table 1 . The median age of all patients was 65 years (range, 37-85 years), and 72 of the 124 patients (58.1%) were women. In addition, 47.1% of the patients were never smokers. Most of the patients had adenocarcinoma (96.0%). The most common mutation (50.8%) was the L858R mutation in exon 21, followed by a deletion in exon 19 (39.5%). Of the 124 patients, 107 (86.3%) had a response to EGFR-TKI treatment (noneprimary resistance) and 17 (13.7%) exhibited primary resistance. None of the patients had T790M at the diagnosis. Significant differences between primary resistance and noneprimary resistance were found in sex and smoking history (P < .001). We performed multivariate analysis to adjust the effect of sex on smoking history. On multivariate analysis, a positive smoking history correlated significantly with primary resistance (P ¼ .040). Of the 17 patients with primary resistance and 107 patients with noneprimary resistance, 9 (52.9%) and 57 (53.3%) received systemic therapy after EGFR-TKI treatment, respectively (data not shown). The OS was significantly shorter for those with primary resistance compared with that for those with noneprimary resistance (median, 11.6 months; 95% confidence interval [CI], 3.2-19.0 months; vs. median, 31.6 months; 95% CI, 24.9-37.4; P < .001; Figure 1 ).
TIL Density
To clarify whether TIL density was related to primary resistance, we immunohistochemically assessed the density of CD4-positive (CD4 , respectively (Supplemental Figure 1 ; available in the online version). We used the median density of the CD4 þ TILs,
CD8
þ TILs, and total TILs as cutoff points to divide the 79 patients into high or low infiltration groups classified by T-cell subsets in tumor areas. The relationship between TIL density and primary resistance is presented in Table 2 . No significant correlation was observed between primary resistance and the density of CD4 þ TILs.
A lower density of CD8 þ TILs was observed in patients with primary resistance compared with those with noneprimary resistance, although the difference was not statistically significant (P ¼ .087). In addition, a lower density of total TILs correlated significantly with primary resistance compared with noneprimary resistance (P ¼ .014). In the present study, no significant correlation was found between smoking status and the density of total TILs (median, 63. 
PD-L1 Expression on TCs and ICs
Immunohistochemical assessment of PD-L1 expression was performed in 84 specimens. Positive staining for PD-L1 was observed in the membrane of TCs and ICs ( Figure 2C, D) . The NSCLC With Primary Resistance to EGFR-TKIs distribution of PD-L1 expression patterns on TCs and ICs is summarized in Figure 3 . In all cases, 81% (68 of 84), 2% (2 of 84), 11% (9 of 84), and 6% (5 of 84) of the samples were designated as TC0, TC1, TC2, and TC3, respectively, and 52% (44 of 84), 27% (23 of 84), 13% (11 of 84), and 7% (6 of 84) were designated as IC0, IC1, IC2, and IC3, respectively. The relationship between PD-L1 expression and primary resistance is listed in Table 3 . We defined TC1/2/3 or IC1/2/3 (PD-L1 expression, ! 1% of TCs or ICs) as positive PD-L1 expression, in accordance with a previous study. 20 Negative PD-L1 expression correlated significantly with primary resistance compared with noneprimary resistance (P ¼ .046). In the present study, no significant correlation was found between smoking status and PD-L1 expression (P ¼ .827; Supplemental Using on a previously reported classification of the tumor microenvironment according to the TIL and PD-L1 status, 21 we divided patients into 2 groups: negative PD-L1 expression with low TIL density (density of total TILs), and other. We observed that a combination of negative PD-L1 expression and low TIL density correlated significantly with primary resistance compared with noneprimary resistance (P ¼ .006; Table 4 ).
Discussion
The results of the present study have shown that the rate of smoking is greater in those with primary resistance to EGFR-TKIs compared with those with noneprimary resistance. Moreover, the immunohistochemical analysis showed that a lower density of TILs and PD-L1
À status was observed in those with primary resistance.
The present study revealed that PD-L1 expression on TCs and ICs was lower in those with primary resistance than in those with noneprimary resistance. Several studies have examined the correlation between PD-L1 expression on TCs and treatment outcomes in EGFR-TKIetreated NSCLC patients with EGFR mutations, [22] [23] [24] although the results were contradictory. It has been reported that in NSCLC patients with EGFR mutations, high PD-L1 expression on TCs was associated with a better response to EGFR-TKIs and longer progression-free survival (PFS) and OS. 22, 23 In contrast, Tang et al 24 reported that no correlation was found between the expression of PD-L1 and EGFR-TKI efficacy in those with NSCLC with EGFR mutations. 24 Moreover, the expression of PD-L1 on TCs and ICs, and its effect on the response to EGFRTKIs in NSCLC with EGFR mutations have not been adequately investigated. Soo et al 25 reported that PD-L1 expression on TCs and ICs analyzed using SP142, similar to our study, was not associated with the response to EGFR-TKIs in NSCLC with EGFR mutations. A comparison of the results from the study by Soo et al 25 and those from our study showed the following: TC0 status in 43% and 81% of the cases and IC3 status in 0% and 7% of the cases, respectively. Furthermore, in the study by Soo et al, 25 all the patients had a new diagnosis and were treatment naive. This difference in the distribution of PD-L1 expression patterns and patient characteristics might reflect the inconsistency of the association between PD-L1 expression on TCs and ICs and the efficacy of EGFR-TKIs. The status of TILs is considered to be an important prognostic parameter in a variety of cancers. Previously, a high incidence of CD4 þ and CD8 þ TILs was reported to be a significant prognostic factor in NSCLC. 26 The present study showed that low total TILs OS. The inconsistency between our results and those from other reports might have resulted from a difference in the T-cell subsets examined, in addition to differences in patient characteristics. Furthermore, our immunohistochemistry analysis revealed that a tumor microenvironment with a low total TIL density and an absence of PD-L1 expression was significantly linked with primary resistance. To the best of our knowledge, ours is the first study to investigate the association between primary resistance to EGFR-TKIs and tumor microenvironment parameters such as TIL density and/or PD-L1 expression. The classification of tumors into 4 groups according to PD-L1 status and the presence or absence of TILs has been previously in promoting immune tolerance). Some studies of melanoma have reported that patients with a type II microenvironment are predicted to have a very poor prognosis owing to the lack of a detectable immune reaction. 21 In the present study, patients with primary resistance also had poor survival compared with those with noneprimary resistance, indicating that a type II microenvironment might underlie primary resistance to EGFR-TKIs and the poor prognosis. Recently, several immune checkpoint inhibitors including an antiePD-1/PD-L1 antibody and an antieCTLA-4 antibody, have been reported to show efficacy in NSCLC. 14, 15, [28] [29] [30] Gainor et al 31 reported that patients with EGFR mutations showed low colocalization of PD-L1 expression and TILs and a low response to PD-1/PD-L1 inhibitors. Our data suggest that primary resistance was significantly associated with an immune ignorant status among patients with EGFR mutations. Thus, in such patients, combination therapy designed to promote T-cell infiltration into tumors and further help preserve their activity, such as a combination of antieCTLA-4 and antiePD-1 antibodies, would be an effective immunotherapeutic modality. However, the detailed relationship between a type II microenvironment and primary resistance is still unknown, and further investigations are required to validate our results and proposed mechanisms.
In the present study, we found that a positive smoking history was significantly linked to primary resistance, consistent with the result of previous studies that cigarette smoke decreased the objective response rate, disease control rate, and PFS in NSCLC patients treated with EGFR-TKIs. [32] [33] [34] [35] A potential explanation for the poor 
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Clinical Lung Cancer July 2018 -357 response to EGFR-TKIs in smokers is the possibility of activating EGFR mutations that can result from smoking. A previous report has suggested that activation of the nicotinic acetylcholine receptor by cigarette smoking might have increased extracellular signalregulated kinase and Akt signaling, leading to EGFR-TKI resistance. 36 In addition, it has been reported that the rate of genetic alteration in smokers with NSCLC was greater than that in never smokers and activated the pathway that was not inhibited by EGFRTKIs. 37 Although the present study is the first comprehensive analysis of smoking status, the expression of PD-L1 and TIL density in primary resistance to EGFR-TKIs and further investigation is required, smoking could have a negative effect on the tumor immune microenvironment in primary resistance. Our study had several limitations and possible biases. First, because of the limited small sample size, the statistical significance was marginal. Second, because of its retrospective nature, the patient selection and time trend biases regarding the diagnosis of disease progression and treatment might be inevitable. Additionally, we did not investigate the potential genetic or molecular alterations related to the primary resistance (eg, MET amplification, PTEN loss) and the correlation between these alterations and the tumor immune microenvironment.
Conclusion
In the present study, we found that a positive smoking history correlated significantly with primary resistance to EGFR-TKIs. We found that a tumor immune microenvironment characterized by a low total TIL density and/or negative PD-L1 expression correlated significantly with primary resistance. These results suggest that immune ignorance in the tumor microenvironment might result in primary resistance to EGFR-TKI therapy.
Clinical Practice Points
In NSCLC, the patient characteristics and immune microenvironmental features in primary resistance to EGFR-TKI are unclear. A lower density of TILs and PD-L1 À status were observed in those with primary resistance; also, the rate of smoking was greater in those with primary resistance. Few studies have directly focused on the relationship between the tumor immune microenvironment and primary resistance to EGFR-TKIs. We found that a tumor immune microenvironment characterized by a low total TIL density and/or negative PD-L1 expression correlated significantly with primary resistance.
To the best of our knowledge, ours is the first study to investigate the association between primary resistance to EGFR-TKIs and tumor microenvironment parameters, such as the TIL density and/or PD-L1 expression.
Our results suggest that immune ignorance in the tumor microenvironment might result in primary resistance to EGFR-TKI therapy; thus, in such patients, combination therapy designed to promote T-cell infiltration into tumors and further help preserve their activity, such as a combination of antieCTLA-4 and antiePD-1 antibodies, would be an effective immunotherapeutic modality. TC staining score represents staining positivity: TC0, < 1%; TC1, ! 1% to < 5%; TC2, ! 5% to < 50%; and TC3, ! 50%; IC staining score represents staining positivity: IC0, < 1%; IC1, ! 1% to < 5%; IC2, ! 5% to < 10%; and IC3, ! 10%. Abbreviations: EGFR ¼ epidermal growth factor receptor; IC ¼ immune cell; PD-L1 ¼ programmed cell death ligand 1; TC ¼ tumor cell; TKI ¼ tyrosine kinase inhibitor. a Statistically significant. 
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Supplemental 20 19 TC staining score represents staining positivity: TC0, < 1%; TC1, ! 1% to < 5%; TC2, ! 5% to < 50%; and TC3, ! 50%; IC staining score represents staining positivity: IC0, < 1%; IC1, ! 1% to < 5%; IC2, ! 5% to < 10%; and IC3, ! 10%. Abbreviations: IC ¼ immune cell; PD-L1 ¼ programmed cell death ligand 1; TC ¼ tumor cell. a Differences were statistically significant at P ¼ .827.
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